Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2449-2462
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2449
Figure 4
Figure 4 Gene mutation profile of patients who achieved complete response or had progression-free survival greater than 6 months. F: Fruquintinib; R: Regorafenib; FP: Fruquintinib plus programmed death-1 inhibitors; RP: Regorafenib plus programmed death-1 inhibitors.